Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Revenue (2016 - 2025)

Vanda Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $57.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 7.58% year-over-year to $57.2 million; the TTM value through Dec 2025 reached $216.1 million, up 8.72%, while the annual FY2025 figure was $216.1 million, 8.72% up from the prior year.
  • Revenue for Q4 2025 was $57.2 million at Vanda Pharmaceuticals, up from $56.3 million in the prior quarter.
  • Across five years, Revenue topped out at $70.1 million in Q3 2021 and bottomed at $38.8 million in Q3 2023.
  • The 5-year median for Revenue is $56.7 million (2025), against an average of $56.5 million.
  • The largest annual shift saw Revenue tumbled 40.58% in 2023 before it rose 22.76% in 2024.
  • A 5-year view of Revenue shows it stood at $68.0 million in 2021, then fell by 5.2% to $64.5 million in 2022, then dropped by 29.79% to $45.3 million in 2023, then increased by 17.48% to $53.2 million in 2024, then increased by 7.58% to $57.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Revenue are $57.2 million (Q4 2025), $56.3 million (Q3 2025), and $52.6 million (Q2 2025).